All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Wall Street seemed to respond with thumbs down to positive data from the phase II study called Vadis with Sellas Life Sciences Group Inc.’s nelipepimut-S (NPS, or NeuVax) in breast ductal carcinoma in situ (DCIS), but the apparent reaction likely had little to do with the trial findings.